A2 Biotherapeutics nabs $71M-plus Series B for selective cell therapy pipeline
More than 15 years after beating cancer himself, A2 Biotherapeutics CEO Scott Foraker has pulled in a $71.5 million Series B round to send a mystery candidate for solid tumors into the clinic.
“It’s quite personal for me and I really am driven to make a difference,” said Foraker, a non-Hodgkin’s lymphoma survivor. “I know what it’s like to sit in an infusion chair for hours and get doses of chemotherapy.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
